Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPensionProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMCQF) Cash & Equivalents (2016 - 2025)

Fresenius Medical Care AG has reported Cash & Equivalents over the past 17 years, most recently at $1.9 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $1.9 billion for Q4 2025, up 47.6% from a year ago — trailing twelve months through Dec 2025 was $1.9 billion (up 47.6% YoY), and the annual figure for FY2025 was $1.9 billion, up 47.6%.
  • Cash & Equivalents for Q4 2025 was $1.9 billion at Fresenius Medical Care AG, up from $1.3 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for FMCQF hit a ceiling of $1.9 billion in Q4 2025 and a floor of $1.3 billion in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $1.5 billion (2023), compared with a mean of $1.5 billion.
  • Biggest five-year swings in Cash & Equivalents: dropped 23.33% in 2022 and later soared 47.6% in 2025.
  • Fresenius Medical Care AG's Cash & Equivalents stood at $1.7 billion in 2021, then fell by 23.33% to $1.3 billion in 2022, then increased by 18.16% to $1.5 billion in 2023, then decreased by 17.87% to $1.3 billion in 2024, then skyrocketed by 47.6% to $1.9 billion in 2025.
  • The last three reported values for Cash & Equivalents were $1.9 billion (Q4 2025), $1.3 billion (Q4 2024), and $1.5 billion (Q4 2023) per Business Quant data.